REG - Oxford Biomedica PLC - PDMR Dealings

Oxford BioMedicaAnnouncement

03/07/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230703:nRSC8078Ea&default-theme=true

RNS Number : 8078E  Oxford Biomedica PLC  03 July 2023

 

 

PDMR Dealings

 

Oxford, UK - 3 July 2023: Oxford Biomedica plc ("Oxford Biomedica" or " the
Company") (LSE:OXB), a quality and innovation-led viral vector CDMO, today
announces that Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston
and Catherine Moukheibir have purchased ordinary shares in the Company
pursuant to a trading plan put in place on 7 October 2022.

 

By way of background, and as stated in the Oxford Biomedica 2021 Remuneration
Policy which was approved at the 2021 Annual General Meeting, an additional
fee of up to £50,000 per annum may be paid to any Non-Executive Director
recruited from or based outside of the UK to reflect market levels of
remuneration for Non-Executive Directors not based in the UK, subject to
their agreement that the after tax amount of this additional fee will be used
to acquire Oxford Biomedica shares at market value, which must be retained for
at least 12 months from acquisition. The ordinary shares were all purchased at
430p and the number of ordinary shares purchased along with further
information is set out in the table below:

 

 Name of PDMR         Number of ordinary shares purchased  Number of ordinary shares now held  Total number of ordinary shares held as a percentage of the Company's share
                                                                                               capital
 Dr. Michael Hayden   6,684                                17,973                              0.019
 Dr. Heather Preston  6,684                                18,298                              0.019
 Cathrine Moukheibir  6,684                                18,530                              0.019

 

The below notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the number of ordinary shares
purchased.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Michael Hayden
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £4.30     6,684

 e)  Aggregated information

     -    Aggregate volume                    6,684

     -    Aggregated total

                                              £28,741.20
 f)  Date of the transaction                  2023-07-03
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

6,684

 

£28,741.20

f)

Date of the transaction

2023-07-03

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Heather Preston
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £4.30     6,684

 e)  Aggregated information

     -    Aggregate volume                    6,684

     -    Aggregated total

                                              £28,741.20
 f)  Date of the transaction                  2023-07-03
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

6,684

 

£28,741.20

f)

Date of the transaction

2023-07-03

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Catherine Moukheibir
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £4.30     6,684

 e)  Aggregated information

     -    Aggregate volume                    6,684

     -    Aggregated total

                                              £28,741.20
 f)  Date of the transaction                  2023-07-03
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

6,684

 

£28,741.20

f)

Date of the transaction

2023-07-03

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , www.oxbsolutions.com (https://oxbsolutions.com/) ,
and follow us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/)
, Twitter (https://twitter.com/OxfordBioMedica) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFFEDEIVIIV